Los Angeles Capital Management’s Neurogene NGNE Stock Holding History

Los Angeles Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$278K	Sell	13,793 -737	-5%	-$14.3K	﹤0.01%	1053
2025 Q4	$482K	Buy	+14,530	New	+$362K	﹤0.01%	907
2022 Q1	–	Sell	-2,573	Closed	-$248K	–	1464
2021 Q4	$248K	Buy	2,573 +441	+21%	+$53.7K	﹤0.01%	1303
2021 Q3	$308K	Sell	2,132 -186	-8%	-$28.5K	﹤0.01%	1298
2021 Q2	$428K	Buy	2,318 +948	+69%	+$210K	﹤0.01%	1247
2021 Q1	$337K	Buy	1,370 +394	+40%	+$101K	﹤0.01%	1394
2020 Q4	$275K	Buy	+976	New	+$238K	﹤0.01%	1397

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Los Angeles Capital Management's NGNE Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Neurogene (NGNE) stake by 5.1% in Q1 2026, selling an estimated $14.3K and leaving 13,793 shares worth $278K. The position accounts for ﹤0.01% of the portfolio, ranked #1053.

Los Angeles Capital Management first reported a position in NGNE in Q4 2020 and has held it in 7 quarters since. The position peaked at $482K in Q4 2025. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

Los Angeles Capital Management held 13,793 shares of Neurogene worth $278K as of Q1 2026.
Los Angeles Capital Management sold 737 Neurogene shares in Q1 2026, an estimated $14.3K.
Neurogene made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1053 holding.
Los Angeles Capital Management first reported a position in Neurogene in Q4 2020 and has held it in 7 quarters since.
Los Angeles Capital Management's Neurogene position peaked at $482K in Q4 2025.
96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.